Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UQQ1

UPID:
NALDL_HUMAN

ALTERNATIVE NAMES:
100 kDa ileum brush border membrane protein; Ileal dipeptidylpeptidase; N-acetylated-alpha-linked acidic dipeptidase-like protein

ALTERNATIVE UPACC:
Q9UQQ1; C9J8A1; C9J964; C9JL35; C9JSN0; O43176

BACKGROUND:
The enzyme Aminopeptidase NAALADL1, recognized for its alternative names such as Ileal dipeptidylpeptidase, showcases a broad substrate specificity, excluding substrates with Pro at P3' and Asp or Glu at P2' positions. This specificity highlights its potential role in digestive processes and protein metabolism.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Aminopeptidase NAALADL1 offers a promising avenue for drug discovery. Its unique substrate specificity and enzymatic actions present opportunities for developing novel therapeutic agents that could modulate its activity for treating metabolic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.